RBRK
Rubrik, Inc.
$114.59
+1.04% 2026-10-20
Technology
RBRKSPY
1W
-3.3%
1M
+7.4%
3M
+51.2%
6M
+112.1%
YTD
+49.8%
1Y
+45.4%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsPreply Strengthens U.S. Leadership Team with Two Executive Appointments to Support Next Phase of Global Growth
PR Newswire · Oct 14
Rubrik Expands AI Security Partnership With Code Guardian Launch
MT Newswires · Oct 09
Rubrik Expands Project Hourglass as Selling Costs Fall Relative to Revenue
TIKR · Oct 09
Rubrik Expands Project Hourglass with Rubrik Code Guardian, Powered by Claude
Business Wire · Oct 08
OpenAI Takes Another Executive from Musk’s SpaceX as It Pushes into Global Sales
Benzinga Private Markets · Oct 08
Key stats
Market cap$23.6B
P/E (trailing)–
P/E (forward)149.3
52-week range42.25 – 127.90
Revenue growth (YoY, latest qtr)+37.9%
Dividend yield0.00%
Analyst consensusNone (27)
Mean price target$120.15 (+5%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -2 (DCF counts double).
▼DCF (base case)below the price by 16%
•Piotroski F-score6/9
▲Altman Z3.2 (safe)
•Analyst target+5% (27 analysts)
Discounted cash flow
Bear
$47
-59%
growth 18% · disc. 10.8% · term. 2.0%
Base
$96
-16%
growth 30% · disc. 9.8% · term. 2.5%
Bull
$172
+50%
growth 38% · disc. 8.8% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 25% a year for 10 years.
Implied
+25%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
+30%/yr
Revenue, last 5 yrs
n/a
Same inputs as the DCF above: trailing free cash flow 0.3B, 9.8% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2026; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-07-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.12 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $0.77 vs trailing $-1.27. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$2.6B
as of 2026-07-31
vs a year ago
+30%
YoY
× TTM revenue
1.70×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
80.2%
Operating margin
-18.3%
FCF margin
19.7%
Net margin
-16.5%
Return on equity
–
Return on invested capital
–
Net debt / EBITDA
–
Current ratio
1.6×
Interest cover
-65.0×
Cash conversion (OCF/NI)
–
Piotroski F-score 6/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✓ Gross margin improved✗ Asset turnover improved
Altman Z-score 3.2 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$120
+5%
Analysts
27
None
Range
$110–$139
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | $1.3B | $-348.8M | $253.3M |
| 2025 | $886.5M | $-1.2B | $31.3M |
| 2024 | $627.9M | $-354.2M | $-16.9M |
| 2023 | $599.8M | $-277.7M | $-5.7M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +29.9%.
Earnings
Next report: 2026-12-03 · during market · EPS est 0.08
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-27 | 0.04 | 0.20 | +409.6% |
| 2026-06-04 | -0.03 | 0.16 | +668.0% |
| 2026-03-12 | -0.11 | 0.04 | +136.8% |
| 2025-12-04 | -0.17 | 0.10 | +158.0% |
| 2025-09-09 | -0.34 | -0.03 | +91.2% |
| 2025-06-05 | -0.32 | -0.15 | +53.0% |
| 2025-03-13 | -0.39 | -0.18 | +53.7% |
| 2024-12-05 | -0.40 | -0.21 | +47.3% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-07-31 | $427.3M | +37.9% |
| 2026-04-30 | $387.1M | – |
| 2026-01-31 | $377.7M | – |
| 2025-10-31 | $350.2M | – |
| 2025-07-31 | $309.9M | – |
Analyst actions
Baird
PT $139
2026-09-23 · main
Outperform → OutperformPT $139
CIBC
PT $120
2026-08-31 · main
Outperformer → OutperformerPT $120
Scotiabank
PT $120
2026-08-28 · main
Sector Outperform → Sector OutperformPT $120
Citigroup
PT $130
2026-08-28 · main
Buy → BuyPT $130
Piper Sandler
PT $114
2026-08-28 · main
Overweight → OverweightPT $114
Barclays
PT $115
2026-08-28 · main
Overweight → OverweightPT $115
Insider trades
Nithrakashyap Arvind
$182.3K
Director, Chief Technology Officer · 2026-10-07
SELL$182.3K
Nithrakashyap Arvind
$1.0M
Director, Chief Technology Officer · 2026-10-07
SELL$1.0M
Nithrakashyap Arvind
$381.2K
Director, Chief Technology Officer · 2026-10-07
SELL$381.2K
Nithrakashyap Arvind
$1.6K
Director, Chief Technology Officer · 2026-10-07
SELL$1.6K
Nithrakashyap Arvind
$73.0K
Director, Chief Technology Officer · 2026-10-06
SELL$73.0K
Nithrakashyap Arvind
$1.4M
Director, Chief Technology Officer · 2026-10-06
SELL$1.4M
Nithrakashyap Arvind
$135.6K
Director, Chief Technology Officer · 2026-10-06
SELL$135.6K
Nithrakashyap Arvind
$8.7K
Director, Chief Technology Officer · 2026-10-06
SELL$8.7K
Nithrakashyap Arvind
$58.9K
Director, Chief Technology Officer · 2026-10-05
SELL$58.9K
Nithrakashyap Arvind
$13.2K
Director, Chief Technology Officer · 2026-10-05
SELL$13.2K
Nithrakashyap Arvind
$109.2K
Director, Chief Technology Officer · 2026-10-05
SELL$109.2K
Nithrakashyap Arvind
$341.6K
Director, Chief Technology Officer · 2026-10-05
SELL$341.6K
Stats refreshed 2026-10-20 18:13:47 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.